I'm also disappointed in the lack of news flow for the burns study. The market for topical may be smaller, but it should have been the fastest/easiest to get to market.
A topical product in the market could be massive, easily cash flowing all R&D for other products/indications plus profit.
Also, feeling a bit uncertain about the pure sepsis opportunity given the low peak serum concentrations. Compare them to the MICs of various bugs in the pre-clinical slides.
Ann: Anti-Infective Portfolio Update and Webinar details, page-9
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
37.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $108.4M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 16210 | 3 |
View Market Depth
| Last trade - 10.22am 08/08/2025 (20 minute delay) ? |
| RCE (ASX) Chart |
Day chart unavailable